Status:
COMPLETED
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
Lead Sponsor:
Desitin Arzneimittel GmbH
Conditions:
Epilepsy
Eligibility:
All Genders
12+ years
Brief Summary
Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets. As a multiple unit dosage form these can be easily swa...
Eligibility Criteria
Inclusion
- age of 12 years and above
- epilepsy patients
- indication to initiation / conversion to valproate sustained release minitablets once daily
Exclusion
- contraindication to valproate use
- no indication for conversion to valproate sustained release minitablets once daily
Key Trial Info
Start Date :
January 1 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2006
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT00870688
Start Date
January 1 2005
End Date
April 1 2006
Last Update
May 20 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.